✦ LIBER ✦

PCN41 ECONOMIC OUTCOMES AMONG 2ND LINE NON-SMALL CELL LUNG CANCER PATIENTS IN THE OUTPATIENT COMMUNITY SETTING

✍ Scribed by S Gruschkus; C Reyes; M Forsyth; A Ravelo; E Nadler

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

HE1 COST-EFFECTIVENESS OF 1ST LINE CHEMO

✍ JR Hoverman; G Pohl; SK Gruschkus; M Marciniak; M Forsyth; G Peltz 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

PCN13 REAL LIFE OUTCOMES IN 2ND LINE ADV

✍ A. Vergnenegre; D.F. Heigener; H.G. Bischoff; C. Chouaid; G. Taylor-Stokes; A. R 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

9114 POSTER Patient Characteristics in a

✍ Nadler, E.; Chen, C.; Forsyth, M.; Penrod, J.R.; Corral, M.; Salvati, M. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 38 KB

20 An audit of docetaxel for 2nd line tr

✍ Capaldi, S.; Lord, H.; Rankin, E.M.; Brown, E. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Use of erlotinib in patients selected us

✍ Stavridi, F.; Eestila, S.; Merchant, S.; Cane, P.; Spicer, J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Second- and Third-line Treatment of Pati

✍ Edward J. Stepanski; Arthur C. Houts; Lee S. Schwartzberg; Mark S. Walker; Carol 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 260 KB